0001209191-13-032020.txt : 20130613
0001209191-13-032020.hdr.sgml : 20130613
20130613155210
ACCESSION NUMBER: 0001209191-13-032020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130612
FILED AS OF DATE: 20130613
DATE AS OF CHANGE: 20130613
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 100
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 100
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EVNIN LUKE
CENTRAL INDEX KEY: 0001134657
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 13911463
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2013-06-12
0
0001396814
Pacira Pharmaceuticals, Inc.
PCRX
0001134657
EVNIN LUKE
C/O MPM ASSET MANAGEMENT
200 CLARENDON STREET, 54TH FLOOR
BOSTON
MA
02116
1
0
0
0
Common Stock
2013-06-12
4
S
0
2435
30.00
D
20311
D
Common Stock
2013-06-13
4
S
0
20311
30.0745
D
0
D
Common Stock
824255
I
See Footnote
Director Stock Option (Right to Buy)
29.90
2013-06-12
4
A
0
7000
0.00
A
2023-06-12
Common Stock
7000
7000
D
This transaction was pursuant to a 10b5-1 Plan.
Represents the average sales price. The shares were sold between $30.00 and $30.38. The Reporting Person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 772,568 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 29,769 by by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 21,918 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The option vests in twelve equal monthly installments following the vesting commencement date of June 12, 2013.
/s/ Luke Evnin
2013-06-13